Patients Stopping Anti-Obesity Injections Put On Pounds Far More Rapidly Compared to Those on Conventional Diets

A recent study reveals that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.

Findings released in a leading medical journal shows that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.

"Individuals purchasing such medications need to be cognizant of the danger of quick rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.

This pace of regain means a return to starting weight in about a year and a half.

Weighing Approaches

The analysis, which looked at 37 of studies involving thousands of patients, contrasted the effects of these new drugs with conventional dieting.

The team point out that people who lose weight through diet and exercise generally see a more gradual creep back—around 0.1 kg a month—post-intervention.

Understanding the Rapid Rebound

Doctors suggest the mechanism of the injections explains the heightened weight return.

These medications copy a natural hormone called GLP-1, which controls appetite.

"Sustained high doses of the hormone concentrations far above than normal could lead to the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating far more likely."

An Ongoing Condition?

Medical guidelines suggest the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.

A number of clinicians argue that, considering the significant potential of weight regain, the treatment should be considered life-long.

This perspective is supported by drug manufacturers, who state that the results "highlight the persistent character of obesity," similar to managing conditions like high blood pressure.

User Experiences

People who have come off the jabs explain a sudden return of cravings.

"I experienced something that goes on and I was suddenly ravenous," recalled an individual.

This challenge is worsened if individuals have not developed lasting dietary or behavioural changes during therapy.

Growing Adoption

Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.

• Adoption is higher among women than men.
• The 40s and 50s demographic shows the highest usage rates.
• Many obtain the drugs through private healthcare rather than the NHS.

Ultimately, researchers caution that while these medications are potent tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on integrated lifestyle changes.